EOC Pharma, a biotech operating out of the US and China, has announced that a clinical trial filing for its CDK7 inhibitor EOC237 has been accepted for review by the Center for Drug Evaluation (CDE) in China. This marks a significant milestone in the development of EOC237, which is expected to enter a Phase I clinical study this year to treat advanced solid tumors.
EOC237: Safety and Efficacy
According to the press release, EOC237 has shown better safety and higher anti-tumor activity than similar products in both in vivo and in vitro studies. This molecule has the potential to become the first of its kind to enter clinics in China, offering a new treatment option for patients with advanced solid tumors.
Indications and Pre-Clinical Studies
Breast cancer is one of the most promising indications for CDK7 inhibitors, including both estrogen receptor-positive (ER+) breast cancer and triple-negative breast cancer (TNBC). In addition, CDK7 inhibitors have proved to be efficacious in pre-clinical studies in pancreatic cancer, epithelial ovarian cancer, small cell lung cancer, non-small cell lung cancer, and castration-resistant prostate cancer. Cancer cell lines amplified in MYC, such as liver cancer, pancreatic cancer, neuroblastoma, small cell lung cancer (SCLC), and TNBC, are highly sensitive to CDK7 inhibitors, making EOC237 a potentially valuable treatment for these conditions.-Fineline Info & Tech
